Omicron Variant Covid-19 Patients Can’t Get These 2 Drugs Therapy!

Suara.com – The World Health Organization or WHO has just released the latest guidelines, that Covid-19 patients infected with the Omicron variant should not be given the antibody therapy drugs Casirivimab and Imdevimab.

Casirivimab and Imdevimab are laboratory-made monoclonal antibody or immune cell protein therapies, specifically designed to fight the SARS CoV 2 virus.

Casirivimab and Imdevimab are therapeutic treatments for COVID-19 patients with mild symptoms, made by Regeneron Pharmaceuticals Inc, and have received emergency clearance from the US BPOM, namely the FDA.

Through its official statement, Thursday (3/3/2022), WHO said that Casirivimab and Imdevimab therapy are two combinations of antibodies that have not been shown to be effective against the Omicron variant.

Also Read:
The Number of Patients in Isoter, Guntung Bontang Village, Continues to Increase, Dominated by Taman City Company Workers

“WHO now recommends this therapy only be given to Covid-19 infections caused by other variants,” the WHO wrote in a release.

The same thing was conveyed by the FDA, through a revised statement on January 24, 2022, it was stated that antibody therapy even though it had been given an emergency permit, its users could only be limited to Covid-19 patients infected with variants other than Omicron.

Moreover, at this time in the US, cases of Covid-19 are being dominated by 99 percent of the Omicron variant since January 15, 2022, which is actually considered this antibody therapy can be dangerous.

This decision was made by the FDA, to prevent Covid-19 patients from experiencing side effects such as potentially serious allergies, or special, unexpected side effects from exposure to the Omicron variant.

Also Read:
Surabaya City Health Office: Healing Rate of Covid-19 Patients Reached 93 Percent